Alector kicks off biotech IPOs after US government shutdownThe 35-day US government shutdown has not just played havoc at government-run agencies – it has had a Share XAlector kicks off biotech IPOs after US government shutdownhttps://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
Roche cancels two phase III Alzheimer’s trialsRoche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim Share XRoche cancels two phase III Alzheimer’s trialshttps://pharmaphorum.com/news/roche-cancels-two-phase-iii-alzheimers-trials/
United Neuroscience inches closer to Alzheimer’s vaccine prizeA vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to Share XUnited Neuroscience inches closer to Alzheimer’s vaccine prizehttps://pharmaphorum.com/news/united-neuroscience-alzheimers-vaccine/
BioXcel’s agitation drug gets FDA Fast TrackThe FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting Share XBioXcel’s agitation drug gets FDA Fast Trackhttps://pharmaphorum.com/news/bioxcels-agitation-drug-gets-fda-fast-track/
Lilly focuses on tau with AC Immune Alzheimer’s R&D tie-upEli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss Share XLilly focuses on tau with AC Immune Alzheimer’s R&D tie-uphttps://pharmaphorum.com/news/lilly-focuses-on-tau-with-ac-immune-alzheimers-rd-tie-up/
CarThera raises €9m to tackle the blood-brain barrierFrench company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based Share XCarThera raises €9m to tackle the blood-brain barrierhttps://pharmaphorum.com/news/carthera-raises-e9m-to-tackle-the-blood-brain-barrier/
Shinichi Tamura re-takes CEO role at SoseiSosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO Share XShinichi Tamura re-takes CEO role at Soseihttps://pharmaphorum.com/news/shinichi-tamura-re-takes-ceo-role-sosei/
Sosei shares tank after safety issue with Alzheimer’s drugAllergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to Share XSosei shares tank after safety issue with Alzheimer’s drughttps://pharmaphorum.com/news/sosei-shares-tank-after-safety-issue-with-alzheimers-drug/
